NewsMV
ClearBridge Investments identified Thermo Fisher Scientific Inc. (NYSE: TMO) as a notable contributor to its Large Cap Growth Strategy during the third quarter of 2026.
The global equity manager highlighted the life sciences company in its recent investor commentary, noting that Thermo Fisher’s performance helped the strategy outperform its Russell 1000 Growth Index benchmark.
In its Q3 2026 letter, ClearBridge attributed the positive contribution to Thermo Fisher’s continued benefit from a second-quarter earnings beat.
The firm noted that resilient biopharma consumables and pharmaceutical product development end markets, along with healthy third-quarter guidance, support the prospect of an accelerating business into 2027.
Keep reading